Edition:
United States

Olympus Corp (7733.T)

7733.T on Tokyo Stock Exchange

3,660JPY
16 Nov 2018
Change (% chg)

¥5 (+0.14%)
Prev Close
¥3,655
Open
¥3,665
Day's High
¥3,700
Day's Low
¥3,635
Volume
1,045,100
Avg. Vol
1,338,911
52-wk High
¥4,660
52-wk Low
¥3,490

Chart for

About

Olympus Corporation is engaged in the manufacture and sale of precision machineries and instruments. The Company's segments include Medical Business, Scientific Solutions Business, Imaging Business and Others. The Company's Medical Business manufactures and sells medical endoscopes, surgical endoscopes, endotherapy devices and... (more)

Overall

Beta: 1.08
Market Cap(Mil.): ¥1,257,758.00
Shares Outstanding(Mil.): 342.71
Dividend: 30.00
Yield (%): 0.76

Financials

  7733.T Industry Sector
P/E (TTM): 57.82 44.77 29.34
EPS (TTM): 63.47 -- --
ROI: 3.32 6.95 13.58
ROE: 4.99 9.75 15.11

Nikkei rises in volatile trade as investors await U.S. midterm election results

TOKYO, Nov 7 Japan's Nikkei rose in volatile trade on Wednesday morning as investors awaited the results of U.S. midterm elections.

Nov 06 2018

Activist investor ValueAct has $612 million stake in Japan's Olympus

TOKYO U.S. hedge fund ValueAct Capital has become a major shareholder in Japanese medical equipment and camera maker Olympus Corp with a 5.04 percent stake that is worth around $612 million at current shares prices.

May 31 2018

UPDATE 2-Activist investor ValueAct has $612 mln stake in Japan's Olympus

* ValueAct says bought Olympus shares as investment (Adds ValueAct statement)

May 31 2018

U.S. hedge fund ValueAct has 5 pct stake in Japan's Olympus

TOKYO, May 31 U.S. hedge fund ValueAct Capital has become a major shareholder in Japanese medical equipment and camera maker Olympus Corp with a 5.04 percent stake, a regulatory filing showed on Thursday.

May 31 2018

BRIEF-Urogen Pharma Announces Positive Interim Results From Pivotal Phase 3 Olympus Trial Of UGN-101

* UROGEN PHARMA ANNOUNCES POSITIVE INTERIM RESULTS FROM PIVOTAL PHASE 3 OLYMPUS TRIAL OF UGN-101 (MITOGEL™) FOR NON-SURGICAL TREATMENT OF UPPER TRACT UROTHELIAL CANCER (UTUC)

May 21 2018

Earnings vs. Estimates